Skip to main content
PMC home page
RSC Advances logoLink to RSC Advances
. 2018 Jan 9;8(4):1934–1939. doi: 10.1039/c7ra13133j

Eco-friendly polyethylene glycol (PEG-400): a green reaction medium for one-pot, four-component synthesis of novel asymmetrical bis-spirooxindole derivatives at room temperature†

Alireza Hasaninejad 1,✉, Maryam Beyrati 1
PMCID: PMC9077237  PMID: 35542580

Abstract

PEG-400 has been used as a green and biodegradable polymeric solvent for the one-pot, two-step, multi-component synthesis of novel asymmetrical bis-spirooxindole derivatives by the reaction of N-alkyl isatin, isatin derivatives, alkylmalonates and C–H activated carbonyl compounds in the presence of K2CO3 at room temperature. Using this procedure, all the products were obtained in good to excellent yields.

PEG-400 has been used for the synthesis of novel asymmetrical bis-spirooxindoles by the reaction of N-alkyl isatin, isatin derivatives, alkylmalonates and C–H activated carbonyl compounds in the presence of K2CO3 at room temperature.graphic file with name c7ra13133j-ga.jpg

Introduction

In recent years, the development of a high efficiency, high selectivity, green, safe, atom- and step-economical synthesis strategy has become of paramount importance in the field of organic chemistry. One-pot, multi-component reactions are a powerful tool in organic and medicinal chemistry because they can shorten the reaction time, simplify the separation step, reduce costs, and give a relatively higher total chemical yield compared to multistep synthesis.1,2

Solvents are widely used in organic synthesis and have been a cause of major concern due to their associated environmental hazards. Therefore, replacement of harmful organic solvents with an eco-friendly medium is one of the major focal points of green chemistry.3–10 Polyethylene glycol (PEG) and modified polyethylene glycol derivatives have become more popular alternate reaction media, due to their interesting properties like non-toxicity, bio-compatibility, and bio-degradability. Moreover, PEG is considered as a natural, inexpensive, safe, recyclable, degradable, non-flammable, facile, environmentally benign and abundantly available green solvent.11

Spirooxindoles are commonly occurring heterocyclic ring systems and are found in many natural products and pharmaceuticals.12,13 These compounds are known to display anti-tubercular,14 antifungal,15 anti-mycobacterial,16 anti-tumor,17,18 anti-malarial19 and anti-microbial20 activities. Until recently, there have been few reports on the synthesis of symmetric bis-spirooxindole derivatives.21–24 In continuation of our research interest in the synthesis of biologically important heterocyclic compounds,25–33 herein we report a synthetic route for the preparation of novel asymmetrical bis-spirooxindoles 6via a one-pot four-component condensation reaction of N-alkyl isatin 1 (1 eq.), isatin derivatives 2 (1 eq.), alkyl malonates 4 (2 eq.) and C–H activated carbonyl compounds 5 (2 eq.) in the presence of K2CO3 in polyethylene glycol medium at room temperature (Scheme 1).

Scheme 1. The synthesis of novel asymmetrical bis-spirooxindoles 6via the reaction between N-alkyl isatin 1, isatin derivatives 2, alkyl malonates 4 and carbonyl compounds 5 in the presence of K2CO3in PEG-400 at room temperature.

Scheme 1

Open in a new tab

Results and discussion

At first, the N-alkyl isatins 1 were prepared from the reaction of 5-methyl isatin (7, 1 eq.) with dihalidederivatives (8, excess) in the presence of K2CO3 in PEG-400 at room temperature (Scheme 2).

Scheme 2. Synthetic pathway for the synthesis of N-alkyl isatin derivatives.

Scheme 2

Open in a new tab

Then, to optimize the reaction conditions for the synthesis of asymmetrical bis spirooxindole derivatives, the reaction of 1-(4-(chloromethyl)benzyl)-5-methylindoline-2,3-dione (1a), isatin (2a), malononitrile (4a) and 1,3-cyclohexanedione (5b) its behavior was studied in the presence of different catalytic systems, and the results are summarized in Table 1. As it is shown in Table 1, higher yield and shorter reaction time were obtained when the reaction was carried out in the presence of 1 mmol of K2CO3 in PEG-400 at room temperature (Table 1, entry 9).

Effects of reagent and solvent on the reaction of 1-(4-(chloromethyl)benzyl)-5-methylindoline-2,3-dione, isatin, malononitrile and 1,3-cyclohexanedion under different conditionsa.

Entry Reagent reagent (mmol) Solvent Temp. (°C) Time (h) Yield (%)
1 — — PEG-400 r.t. 48 —
2 l-Proline 1.0 PEG-400 r.t. 48 —
3 DABCO 1.0 PEG-400 r.t. 48 —
4 Et3N 1.0 PEG-400 r.t. 48 —
5 Cs2CO3 1.0 PEG-400 r.t. 24 65
6 Na2CO3 1.0 PEG-400 r.t. 24 30
7 NaHCO3 1.0 PEG-400 r.t. 24 —
8 CaCO3 1.0 PEG-400 r.t. 24 25
9 K2CO3 1.0 PEG-400 r.t. 7 95
10 K2CO3 0.5 PEG-400 r.t. 15 70
11 K2CO3 0.8 PEG-400 r.t. 15 87
12 K2CO3 1.5 PEG-400 r.t. 7 94
13 K2CO3 1.0 MeCN r.t. 48 Trace
14 K2CO3 1.0 H2O r.t. 48 —
15 K2CO3 1.0 EtOH r.t. 48 —
16 K2CO3 1.0 MeOH r.t. 24 —
17 K2CO3 1.0 n-Propanol r.t. 24 —
18 K2CO3 1.0 tert-Butanol r.t. 24 —
19 K2CO3 1.0 DMSO r.t. 13 80
20 K2CO3 1.0 DMF r.t. 15 80
21 K2CO3 1.0 — 80 48 —
22 K2CO3 1.0 — 100 48 —
Open in a new tab
a

Isolated yields.

Subsequently, the scope and efficiency of the reagent were explored under the optimized reaction conditions for the condensation of different asymmetrical bis-isatins 3 with a broad range of structurally diverse carbonyl compounds and alkyl malonatesto furnish the related products. The structural diversity of reactants is summarized in Fig. 1 and the results are displayed in Table 2.

Fig. 1. Diversity elements employed for synthesis of asymmetrical bis-spirooxindoles.

Fig. 1

Open in a new tab

One-pot, four-component synthesis of asymmetrical bis-spirooxindole derivatives in the presence of K2CO3 in PEG-400 at room temperaturea.

graphic file with name c7ra13133j-u1.jpg
Open in a new tab
a

Isolated yields.

The synthetic pathway for the synthesis of titled compounds is consisting of two steps. At first, asymmetrical bis-isatin derivatives are obtained from the condensation reaction of N-alkyl isatin 1 and isatin derivatives 2. Then, the resulting products are treated with alkyl malonates 4 and carbonyl compounds 5 to afford the related asymmetrical bis-spirooxindole derivatives as the desired products.

As Table 2 indicates, a variety of isatin derivatives, alkyl malonates and carbonyl compounds were successfully applied in this process to afford the corresponding asymmetrical bis-spirooxindole derivatives as novel and potentially biologically important compounds in excellent yields.

Experimental

All chemicals were purchased from Merck or Fluka chemical companies. The 1H NMR (400 MHz) and 13C NMR (100 MHz) were run on a BrukerAvance400. Melting points were recorded on a Stuart Scientific Apparatus SMP3 (UK) in open capillary tubes. Elemental C, H and N analyses were performed using a Costech CHNS–O elemental analyzer.

General procedure for the synthesis of asymmetrical bisspirooxindolederivatives 6

K2CO3 (1 mmol) was added to a stirred mixture of N-alkylisatin 1 (1 mmol), isatin derivative 2 (1 mmol) in PEG-400 (3 mL) and the reaction mixture was stirred at room temperature to complete the formation of related asymmetrical bis-isatin 3 (monitored by TLC). Subsequently, alkyl malonates 4 (2 mmol) and cyclic ketone 5 (2 mmol) were added to this reaction mixture and reacted at room temperature for the appropriate amount of time (see Table 2). After completion of the reaction, 3 ml of water was added to the reaction mixture; the precipitate was filtrated and recrystallized from hot ethanol to afford the pure products.

2-Amino-1′-(4-((2-amino-3-cyano-5′-methyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indolin]-1′-yl)methyl)benzyl)-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indoline]-3-carbonitrile 6a

White powder, mp > 270 °C, 1H NMR (DMSO-d6,400 MHz) δ (ppm): 1.96 (t, J = 6.0 Hz, 4H), 2.23 (s, 3H), 2.25–2.31 (m, 4H), 2.70–2.73 (m, 4H), 4.88 (d, J = 10.0 Hz, 4H), 6.56 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 7.6 Hz, 1H), 6.93–6.99 (m, 3H), 7.12–7.16 (m, 3H), 7.34 (d, J = 8.8 Hz, 3H), 7.45 (s, 4H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 20.2, 21.1, 27.3, 31.2, 36.8, 43.6, 47.1, 47.2, 57.7, 57.9, 70.3, 109.1, 109.3, 112.2, 112.2, 117.9, 117.9, 123.0, 123.6, 124.2, 127.6, 128.7, 128.9, 131.9, 134.2, 134.2, 135.5, 135.6, 140.7, 143.0, 159.1, 159.2, 159.2, 166.8, 166.9, 177.2, 177.3, 195.6. Anal. calcd for C43H34N6O6: C, 70.67; H, 4.69; N, 11.50%. Found: C, 70.65; H, 4.72; N, 11.48%.

6′-Amino-1-(4-((6′-amino-5′-cyano-3′,5-dimethyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazol]-1-yl)methyl)benzyl)-5-bromo-3′-methyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazole]-5′-carbonitrile 6b

Cream powder, mp > 270 °C, 1H NMR (DMSO-d6,400 MHz) δ (ppm): 0.98 (s, 3H), 1.05 (s, 3H), 2.35 (s, 3H), 4.71 (d, J = 15.6 Hz, 2H), 4.97 (d, J = 15.6 Hz, 2H), 6.65–6.69 (m, 2H), 6.85–7.06 (m, 6H), 7.42 (s, 1H), 7.59 (s, 4H), 7.97 (s, 1H), 12.43 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 21.1, 27.7, 28.0, 32.5, 43.6, 47.1, 50.4, 57.8, 109.2, 128.3, 130.3, 132.5, 133.3, 138.1, 139.0, 139.2, 140.1, 140.2, 142.0, 143.0, 146.3, 147.6, 148.3, 149.7, 149.9, 156.5, 157.1, 159.5, 171.2, 173.0, 173.8. Anal. calcd for C39H29BrN10O4: C, 59.93; H, 3.74; Br, 10.22; N, 17.92%. Found: C, 59.96; H, 3.72; N, 17.90%.

Methyl 2′-amino-1-(4-(2′-amino-3′-(methoxycarbonyl)-5,7′-dimethyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-1-yl)butyl)-5-fluoro-7′-methyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-3′-carboxylate 6c

Cream powder, mp > 270 °C, 1H NMR (DMSO-d6,400 MHz) δ (ppm): 1.49–1.51 (m, 2H), 1.64–1.72 (m, 2H), 2.21 (s, 3H), 2.98 (s, 3H), 3.02 (s, 3H), 3.23 (s, 3H), 3.37 (s, 3H), 3.55–3.64 (m, 2H), 3.71–3.74 (m, 2H), 6.32 (s, 2H), 6.80–6.93 (m, 2H), 6.99–7.00 (m, 1H), 7.11–7.19 (m, 2H), 8.03 (s, 2H), 8.08 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 27.5, 27.7, 28.0, 32.5, 43.5, 47.2, 50.3, 56.9, 110.0, 110.1, 117.7, 121.0, 121.5, 125.5, 127.7, 128.4, 129.3, 130.6, 137.9, 157.6, 159.6, 163.1, 163.9, 165.6, 167.9, 178.6, 195.7. Anal. calcd for C41H35FN4O12: C, 61.96; H, 4.44; F, 2.39; N, 7.05%. Found: C, 61.94; H, 4.42; N, 7.08%.

6′-Amino-1-(4-(6′-amino-5′-cyano-3′,5-dimethyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazol]-1-yl)butyl)-3′-methyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazole]-5′-carbonitrile 6d

Pink powder, mp > 270 °C, 1H NMR (DMSO-d6,400 MHz) δ (ppm): 1.31–1.42 (m, 2H), 1.57–1.65 (m, 2H), 2.05 (s, 3H), 3.08 (s, 6H), 3.60–3.68 (m, 4H), 6.90–6.94 (m, 1H), 6.99 (d, J = 8.4 Hz, 2H), 7.42 (dd, J = 8.4, 2.0 Hz, 4H), 7.49–7.52 (m, 2H), 8.06 (s, 4H), 12.03 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.1, 14.4, 25.0, 44.5, 47.3, 59.3, 62.4, 121.2, 123.4, 125.4, 125.7, 127.0, 127.7, 127.9, 128.3, 130.3, 134.5, 134.7, 135.6, 139.3, 147.4, 152.6, 155.4, 157.5, 158.5, 159.08, 159.3. Anal. calcd for C35H30N10O4: C, 64.21; H, 4.62; N, 21.39%. Found: C, 64.22; H, 4.60; N, 21.41%.

6′-Amino-1-(4-((6′-amino-5′-cyano-5-methyl-2-oxo-3′-propyl-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazol]-1-yl)methyl)benzyl)-5-bromo-2-oxo-3′-propyl-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazole]-5′-carbonitrile 6e

White powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.86–0.92 (m, 3H), 1.02–1.08 (m, 3H), 1.91–1.94 (m, 2H), 2.19–2.25 (m, 2H), 2.69 (s, 3H), 3.01–3.06 (m, 4H), 4.67–4.79 (m, 2H), 4.88–4.99 (m, 2H), 6.65–6.68 (m, 3H), 6.82–6.85 (m, 2H), 6.94 (d, J = 6.8 Hz, 1H), 7.02–7.06 (m, 4H), 7.59 (s, 2H), 7.91 (s, 2H), 12.21 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.1, 14.4, 25.0, 27.1, 28.3, 32.1, 45.0, 46.6, 51.1, 59.0, 62.4, 76.6, 113.9, 114.0, 119.6, 119.7, 124.9, 125.6, 126.1, 129.6, 130.7, 130.9, 133.9, 136.2, 136.2, 137.5, 137.6, 142.6, 144.9, 161.1, 161.2, 161.2, 168.8, 168.9, 179.2, 179.3. Anal. calcd for C43H37BrN10O4: C, 61.65; H, 4.45; Br, 9.54; N, 16.72%. Found: C, 61.67; H, 4.43; N, 16.71%.

Methyl 2′-amino-1-(6-(2′-amino-3′-(methoxycarbonyl)-5,7′-dimethyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-1-yl)hexyl)-5-bromo-7′-methyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-3′-carboxylate 6f

White powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 1.02–1.08 (m, 2H), 1.46–1.49 (m, 2H), 1.59–1.63 (m, 4H), 2.10 (s, 3H), 2.20 (s, 6H), 3.36 (s, 6H), 3.59–3.72 (m, 2H), 6.31 (s, 2H), 6.79 (d, J = 8.4 Hz, 3H), 6.97 (d, J = 7.2 Hz, 2H), 7.60 (d, J = 7.6 Hz, 1H), 8.02 (s, 4H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.0, 19.6, 21.0, 26.7, 27.4, 46.5, 50.9, 59.3, 76.0, 114.2, 125.0, 128.1, 129.3, 129.6, 130.4, 133.3, 135.4, 137.7, 137.8, 138.9, 139.9, 140.2, 142.5, 146.4, 146.7, 147.4, 149.1, 149.4, 159.5, 164.7, 167.4, 170.3, 171.1, 171.1, 174.6. Anal. calcd for C43H39BrN4O12: C, 58.44; H, 4.45; Br, 9.04; N, 6.34%. Found: C, 58.42; H, 4.44; N, 6.36%.

2′-Amino-1-(4-(2′-amino-3′-cyano-5,7′-dimethyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-1-yl)butyl)-7′-methyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[4,3-b]pyran]-3′-carbonitrile 6g

Cream powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 1.03–1.08 (m, 4H), 2.10 (s, 3H), 2.23 (s, 3H), 2.24 (s, 3H), 3.59–3.65 (m, 2H), 3.74–3.80 (m, 2H), 6.34 (s, 2H), 6.86–6.91 (m, 1H), 6.97–7.02 (m, 4H), 7.14–7.20 (m, 2H), 8.09 (s, 4H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.2, 27.2, 28.2, 32.1, 44.4, 46.7, 51.0, 59.1, 76.7, 113.3, 114.3, 114.5, 118.3, 120.2, 122.4, 122.7, 124.2, 124.8, 124.9, 125.3, 127.3, 131.1, 131.7, 132.6, 136.3, 144.3, 149.6, 152.4, 155.5, 155.5, 156.0, 156.3, 169.3. Anal. calcd for C39H30N6O8: C, 65.91; H, 4.25; N, 11.83%. Found: C, 65.89; H, 4.26; N, 11.85%.

Ethyl 2-amino-1′-(4-((2-amino-3-(ethoxycarbonyl)-5′-methyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indolin]-1′-yl)methyl)benzyl)-5′-bromo-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indoline]-3-carboxylate 6h

Pink powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.38 (q, J = 7.2 Hz, 3H), 0.59 (q, J = 7.2 Hz, 3H), 1.92 (t, J = 6.0 Hz, 4H), 2.10 (s, 3H), 2.20–2.30 (m, 4H), 2.69 (t, J = 5.8 Hz, 4H), 3.41–3.49 (m, 2H), 3.76–3.83 (m, 2H), 4.69 (d, J = 16.0 Hz, 2H), 4.97 (dd, J = 15.8, 2.6 Hz, 2H), 6.64 (dd, J = 8.0, 2.4 Hz, 4H), 7.17 (d, J = 1.6 Hz, 1H), 7.25 (d, J = 8.4 Hz, 4H), 7.56 (s, 4H), 8.02 (s, 1H). Sample solubility was too low for 13C-NMR even after heating. Anal. calcd for C47H43BrN4O10: C, 62.46; H, 4.80; Br, 8.84; N, 6.20%. Found: C, 62.47; H, 4.78; N, 6.22%.

2-Amino-1′-(4-((2-amino-3-cyano-5′,7,7-trimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indolin]-1′-yl)methyl)benzyl)-5′-chloro-7,7-dimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indoline]-3-carbonitrile 6i

Cream powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.57 (d, J = 2.4 Hz, 1H), 0.59 (d, J = 2.4 Hz, 1H), 0.99 (s, 3H), 1.04 (s, 3H), 1.23 (s, 3H), 1.25 (s, 3H), 2.90 (s, 2H), 4.66 (d, J = 16.0 Hz, 2H), 4.96 (d, J = 15.6 Hz, 2H), 6.52 (d, J = 7.6 Hz, 3H), 6.75 (s, 1H), 6.85 (d, J = 7.6 Hz, 4H), 7.57 (s, 4H), 7.95 (s, 1H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 10.4, 11.3, 20.2, 21.2, 27.3, 31.2, 36.7, 43.5, 47.1, 47.2, 57.7, 57.9, 70.3, 109.1, 109.3, 112.2, 112.3, 117.9, 117.9, 123.0, 123.6, 124.2, 127.5, 128.8, 128.9, 132.0, 134.2, 134.2, 135.4, 135.6, 140.6, 143.0, 159.2, 159.2, 159.2, 166.8, 166.9, 177.2, 177.3, 192.5, 192.6. Anal. calcd for C47H41ClN6O6: C, 68.73; H, 5.03; Cl, 4.32; N, 10.23%. Found: C, 68.74; H, 5.05; N, 10.21%.

Ethyl 2-amino-1′-(4-((2-amino-3-(ethoxycarbonyl)-5′,7,7-trimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indolin]-1′-yl)methyl)benzyl)-5′-bromo-7,7-dimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indoline]-3-carboxylate 6j

White powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.55 (t, J = 6.4 Hz, 6H), 0.98 (s, 6H), 1.05 (s, 6H), 2.04–2.11 (m, 2H), 2.21 (d, J = 16.0 Hz, 2H), 2.62–2.69 (m, 2H), 2.91 (s, 3H), 3.05 (d, J = 9.6 Hz, 2H), 3.72–3.78 (m, 4H), 4.71 (d, J = 16.4 Hz, 1H), 4.76 (d, J = 16.0 Hz, 1H), 4.90 (d, J = 15.6 Hz, 1H), 4.97 (d, J = 15.6 Hz, 1H), 6.68 (d, J = 3.6 Hz, 2H), 6.86 (d, J = 7.2.0 Hz, 4H), 6.94 (d, J = 6.0 Hz, 2H), 7.05 (s, 1H), 7.59 (s, 4H), 7.95 (d, J = 4.4 Hz, 1H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 13.9, 21.0, 26.2, 27.1, 31.2, 42.8, 46.8, 50.9, 51.1, 53.4, 62.4, 62.5, 76.9, 79.1, 122.9, 123.5, 124.1, 127.5, 128.7, 128.9, 132.0, 134.2, 134.2, 135.4, 135.6, 140.7, 143.0, 159.1, 159.2, 159.2, 166.8, 166.9, 177.2, 177.3, 195.7. Anal. calcd for C51H51BrN4O10: C, 63.82; H, 5.36; Br, 8.32; N, 5.84%. Found: C, 63.81; H, 5.38; N, 5.82%.

Methyl 2′-amino-1-(4-(2′-amino-3′-(methoxycarbonyl)-5-methyl-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[3,2-c]chromen]-1-yl)butyl)-5-bromo-2,5′-dioxo-5′H-spiro[indoline-3,4′-pyrano[3,2-c]chromene]-3′-carboxylate 6k

White powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.67–0.74 (m, 4H), 1.85 (s, 3H), 3.04 (s, 3H), 3.27 (s, 3H), 3.66–3.72 (m, 2H), 3.75–3.82 (m, 2H), 6.86–6.89 (m, 2H), 7.04–7.08 (m, 3H), 7.10 (d, J = 7.2 Hz, 2H), 7.19 (t, J = 7.0 Hz, 1H), 7.47 (d, J = 6.8 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.77 (t, J = 7.8 Hz, 2H), 8.07 (d, J = 8.0 Hz, 1H), 8.21 (s, 4H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.1, 20.1, 27.4, 44.3, 46.8, 50.9, 53.7, 76.7, 113.2, 125.7, 128.0, 129.3, 129.5, 130.6, 133.3, 135.4, 137.7, 137.7, 139.0, 140.9, 141.2, 143.7, 147.2, 147.8, 148.4, 149.1, 149.4, 159.4, 164.6, 167.4, 169.5, 170.1, 170.1, 173.4. Anal. calcd for C47H35BrN4O12: C, 60.85; H, 3.80; Br, 8.61; N, 6.04%. Found: C, 60.87; H, 3.82; N, 6.01%.

Ethyl 6′-amino-1-(4-(6′-amino-5′-(ethoxycarbonyl)-3′,5-dimethyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazol]-1-yl)butyl)-3′-methyl-2-oxo-1′H-spiro[indoline-3,4′-pyrano[2,3-c]pyrazole]-5′-carboxylate 6l

Cream powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.64–0.70 (m, 6H), 0.96 (s, 6H), 1.83 (s, 3H), 2.02–2.06 (m, 2H), 2.59–2.61 (m, 2H), 3.34–3.48 (m, 4H), 3.58–3.64 (m, 2H), 3.72–3.78 (m, 2H), 6.85 (td, J = 7.4, 2.4 Hz, 2H), 6.91–6.95 (m, 3H), 7.11 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 7.6 Hz, 1H), 7.94 (s, 4H), 12.43 (s, 2H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.2, 27.1, 27.2, 28.2, 28.3, 31.2, 32.1, 44.3, 45.2, 46.7, 50.9, 59.1, 76.7, 101.6, 121.3, 124.2, 126.2, 130.7, 131.9, 133.0, 133.0, 135.7, 140.0, 140.4, 141.0, 141.3, 142.8, 152.5, 161.4, 164.2, 167.5, 167.5. Anal. calcd for C39H40N8O8: C, 62.56; H, 5.38; N, 14.96%. Found: C, 62.57; H, 5.40; N, 14.94%.

Methyl 2-amino-1′-(6-(2-amino-3-(methoxycarbonyl)-5′,7,7-trimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indolin]-1′-yl)hexyl)-7,7-dimethyl-2′,5-dioxo-5,6,7,8-tetrahydrospiro[chromene-4,3′-indoline]-3-carboxylate 6m

White powder, mp > 270 °C, 1H NMR (DMSO-d6, 400 MHz) δ (ppm): 0.70 (s, 3H), 0.93 (s, 6H), 1.01 (s, 6H), 1.45–1.52 (m, 2H), 1.61–1.69 (m, 2H), 1.98 (d, J = 15.6 Hz, 2H), 2.11 (d, J = 15.6 Hz, 2H), 2.15 (d, J = 16.0 Hz, 4H), 2.91 (s, 6H), 3.10–3.21 (m, 4H), 3.62 (t, J = 7.0 Hz, 4H), 6.82–6.91 (m, 3H), 7.13 (t, J = 7.6 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 7.88 (s, 4H). 13C NMR (DMSO-d6, 100 MHz) δ (ppm): 14.4, 24.8, 25.0, 27.1, 28.3, 32.1, 42.8, 44.6, 46.8, 50.9, 51.1, 53.4, 62.4, 123.0, 126.5, 128.6, 129.2, 134.3, 135.0, 135.4, 136.1, 136.3, 137.6, 138.9, 142.3, 143.3, 144.5, 145.6, 145.9, 152.5, 153.1, 155.5, 167.2, 169.2, 169.9, 202.5. Anal. calcd for C47H52N4O10: C, 67.77; H, 6.29; N, 6.73%. Found: C, 67.75; H, 6.31; N, 6.72%.

Conclusions

In conclusion, we have reported a highly efficient method for the synthesis of asymmetrical bis-spirooxindole derivatives via a one-pot, two-step, four-component condensation reaction using K2CO3 in PEG-400 as a green and biodegradable polymeric solvent at room temperature.

Conflicts of interest

There are no conflicts to declare.

Supplementary Material

RA-008-C7RA13133J-s001

Acknowledgments

The authors thank Persian Gulf University Research Councils for the financial support of this work.

†

Electronic supplementary information (ESI) available. See DOI: 10.1039/c7ra13133j

References

  1. Zhang M. Fu Q. Gao G. He H. Zhang Y. Wu Y. Zhang Z. ACS Sustainable Chem. Eng. 2017;5:6175–6182. doi: 10.1021/acssuschemeng.7b01102. [DOI] [Google Scholar]
  2. Volla C. M. R. Atodiresei L. Rueping M. Chem. Rev. 2014;114:2390–2431. doi: 10.1021/cr400215u. [DOI] [PubMed] [Google Scholar]
  3. Chandrasekhar S. Narsihmulu C. Shameem Sultana S. Ramakrishna Reddy N. Org. Lett. 2002;4:4399–4401. doi: 10.1021/ol0266976. [DOI] [PubMed] [Google Scholar]
  4. Gu Y. L. Jerome F. Chem. Soc. Rev. 2013;42:9550–9570. doi: 10.1039/C3CS60241A. [DOI] [PubMed] [Google Scholar]
  5. Liu P. Hao J. W. Mo L. P. Zhang Z. H. RSC Adv. 2015;5:48675–48704. doi: 10.1039/C5RA05746A. [DOI] [Google Scholar]
  6. Zhang Q. De Oliveira Vigier K. D. O. Royer S. Jeróm̂e F. Chem. Soc. Rev. 2012;41:7108–7146. doi: 10.1039/C2CS35178A. [DOI] [PubMed] [Google Scholar]
  7. Gawande M. B. Branco P. S. Green Chem. 2011;13:3355–3359. doi: 10.1039/C1GC15868F. [DOI] [Google Scholar]
  8. Li B. L. Li P. H. Fang X. N. Li C. X. Sun J. L. Mo L. P. Zhang Z. H. Tetrahedron. 2013;69:7011–7018. doi: 10.1016/j.tet.2013.06.049. [DOI] [Google Scholar]
  9. Hu H. C. Liu Y. H. Li B. L. Cui Z. S. Zhang Z. H. RSC Adv. 2015;5:7720–7728. doi: 10.1039/C4RA13577F. [DOI] [Google Scholar]
  10. Liu P. Hao J. Zhang Z. Chin. J. Chem. 2016;34:637–645. doi: 10.1002/cjoc.201500862. [DOI] [Google Scholar]
  11. Reddy M. V. Kim J. S. Lim K. T. Jeong Y. T. Tetrahedron Lett. 2014;55:6459–6462. doi: 10.1016/j.tetlet.2014.09.135. [DOI] [Google Scholar]
  12. Galliford C. V. Scheidt K. A. Angew. Chem., Int. Ed. 2007;46:8748–8758. doi: 10.1002/anie.200701342. [DOI] [PubMed] [Google Scholar]
  13. Ding K. Lu Y. P. Coleska N. J. Med. Chem. 2006;49:3432–3435. doi: 10.1021/jm051122a. [DOI] [PubMed] [Google Scholar]
  14. Prasanna P. Balamurugan K. Perumal S. Yogeeswari P. Sriram D. Eur. J. Med. Chem. 2010;45:5653–5661. doi: 10.1016/j.ejmech.2010.09.019. [DOI] [PubMed] [Google Scholar]
  15. Thangamani A. Eur. J. Med. Chem. 2010;45:6120–6126. doi: 10.1016/j.ejmech.2010.09.051. [DOI] [PubMed] [Google Scholar]
  16. Maheswari S. U. Balamurugan K. Perumal S. Yogeeswari P. Sriram D. Bioorg. Med. Chem. Lett. 2010;20:7278–7282. doi: 10.1016/j.bmcl.2010.10.080. [DOI] [PubMed] [Google Scholar]
  17. Ding K. Lu Y. Nikolovska-Coleska Z. Qiu S. Ding Y.-S. Gao W. Stuckey J. Krajewski K. Roller P. P. Tomita Y. Parrish D. A. Deschamps J. R. Wang S.-M. J. Am. Chem. Soc. 2005;127:10130–10131. doi: 10.1021/ja051147z. [DOI] [PubMed] [Google Scholar]
  18. Ding K. Lu Y.-P. Nikolovska-Coleska Z. Wang G.-P. Qiu S. Shangary S. Gao W. Qin D.-G. Stuckey J. Krajewski K. Roller P. P. Wang S.-M. J. Med. Chem. 2006;49:3432–3435. doi: 10.1021/jm051122a. [DOI] [PubMed] [Google Scholar]
  19. Yeung B. K. S. Zou B. Rottmann M. Lakshminarayana S. B. Ang S.-H. Leong S. Y. Tan J. Wong J. Keller-Maerki S. Fischli C. Goh A. Schmitt E. K. Krastel P. Francotte E. Kuhen K. Plouffe D. Henson K. Wagner T. Winzeler E. A. Petersen F. Reto B. Dartois V. Diagana T. T. Keller T. H. J. Med. Chem. 2010;53:5155–5164. doi: 10.1021/jm100410f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nandakumar A. Thirumurugan P. Perumal P. T. Vembu P. Ponnuswamy M. N. Ramesh P. Bioorg. Med. Chem. Lett. 2010;20:4252–4258. doi: 10.1016/j.bmcl.2010.05.025. [DOI] [PubMed] [Google Scholar]
  21. Padvi S. A. Tayade Y. A. Wagh Y. B. Dalal D. S. Chin. Chem. Lett. 2016;27:714–720. doi: 10.1016/j.cclet.2016.01.016. [DOI] [Google Scholar]
  22. Karimi A. R. Abadi R. D. Dalirnasab Z. Res. Chem. Intermed. 2015;41:7427–7435. doi: 10.1007/s11164-014-1834-z. [DOI] [Google Scholar]
  23. Khanna G. Aggarwal K. Khurana J. M. Synth. Commun. 2016;46:1880–1886. doi: 10.1080/00397911.2016.1233437. [DOI] [Google Scholar]
  24. Safari E. Maryamabadi A. Hasaninejad A. RSC Adv. 2017;7:39502–39511. doi: 10.1039/C7RA06017C. [DOI] [Google Scholar]
  25. Beyrati M. Hasaninejad A. Tetrahedron Lett. 2017;58:1947–1951. doi: 10.1016/j.tetlet.2017.04.013. [DOI] [Google Scholar]
  26. Maryamabadi A. Hasaninejad A. Nowrouzi N. Mohebbi G. Bioorg. Med. Chem. 2017;25:2057–2064. doi: 10.1016/j.bmc.2017.02.017. [DOI] [PubMed] [Google Scholar]
  27. Beyrati M. Forutan M. Hasaninejad A. Rakovský E. Babaei S. Maryamabadi A. Mohebbi G. Tetrahedron. 2017;73:5144–5152. doi: 10.1016/j.tet.2017.07.005. [DOI] [Google Scholar]
  28. Maryamabadi A. Hasaninejad A. Nowrouzi N. Mohebbi G. Asghari B. Bioorg. Med. Chem. 2016;24:1408–1417. doi: 10.1016/j.bmc.2016.02.019. [DOI] [PubMed] [Google Scholar]
  29. Beyrati M. Hasaninejad A. Org. Prep. Proced. Int. 2016;48:393–400. doi: 10.1080/00304948.2016.1206426. [DOI] [Google Scholar]
  30. Hasaninejad A. Golzar N. Beyrati M. Zare A. Doroodmand M. M. J. Mol. Catal. A: Chem. 2013;372:137–150. doi: 10.1016/j.molcata.2013.02.022. [DOI] [Google Scholar]
  31. Hasaninejad A. Firoozi S. Mol. Diversity. 2013;17:499–513. doi: 10.1007/s11030-013-9446-x. [DOI] [PubMed] [Google Scholar]
  32. Hasaninejad A. Zare A. Shekouhy M. Ameri Rad J. Green Chem. 2011;13:958–964. doi: 10.1039/C0GC00953A. [DOI] [Google Scholar]
  33. Hasaninejad A. Shekouhy M. Zare A. Hoseini Ghattali S. M. S. Golzar N. J. Iran. Chem. Soc. 2011;8:411–423. doi: 10.1007/BF03249075. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

RA-008-C7RA13133J-s001
RA-008-C7RA13133J-s001.pdf (3.5MB, pdf)

Articles from RSC Advances are provided here courtesy of Royal Society of Chemistry

RESOURCES